249 related articles for article (PubMed ID: 30917983)
1. Results from a Prospective
Fuchs F; Hamprecht A
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917983
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
[TBL] [Abstract][Full Text] [Related]
3. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
Int J Clin Pract; 2019 Sep; 73(9):1-5. PubMed ID: 31243859
[TBL] [Abstract][Full Text] [Related]
4. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
Mohanty S; Gaind R; Ranjan R; Deb M
J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
[TBL] [Abstract][Full Text] [Related]
5. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
Castanheira M; Mills JC; Costello SE; Jones RN; Sader HS
Antimicrob Agents Chemother; 2015; 59(6):3509-17. PubMed ID: 25845862
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
[TBL] [Abstract][Full Text] [Related]
7. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Lampri N; Galani I; Poulakou G; Katsarolis I; Petrikkos G; Giamarellou H; Souli M
J Antimicrob Chemother; 2012 Oct; 67(10):2424-8. PubMed ID: 22665388
[TBL] [Abstract][Full Text] [Related]
8. Activity of mecillinam against carbapenem-resistant Enterobacterales.
Emeraud C; Godmer A; Girlich D; Vanparis O; Mahamdi F; Creton E; Jousset AB; Naas T; Bonnin RA; Dortet L
J Antimicrob Chemother; 2022 Sep; 77(10):2835-2839. PubMed ID: 35815675
[TBL] [Abstract][Full Text] [Related]
9. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model.
Zykov IN; Frimodt-Møller N; Småbrekke L; Sundsfjord A; Samuelsen Ø
Int J Antimicrob Agents; 2020 Feb; 55(2):105851. PubMed ID: 31770624
[TBL] [Abstract][Full Text] [Related]
11. Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?
Bouxom H; Fournier D; Bouiller K; Hocquet D; Bertrand X
Int J Antimicrob Agents; 2018 Jul; 52(1):100-103. PubMed ID: 29580930
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of Clinical Enterobacterales Isolates With Common and Rare Carbapenemases to Mecillinam.
Fuchs F; Ahmadzada A; Plambeck L; Wille T; Hamprecht A
Front Microbiol; 2020; 11():627267. PubMed ID: 33510739
[No Abstract] [Full Text] [Related]
13. Emergence of New Delhi metallo-β-lactamase 1 (NDM-1) producing and multidrug resistant uropathogens causing urinary tract infections in Andaman Islands, India.
Bhattacharya D; Thamizhmani R; Bhattacharya H; Sayi DS; Muruganandam N; Roy S; Sugunan AP
Microb Drug Resist; 2013 Dec; 19(6):457-62. PubMed ID: 23862639
[TBL] [Abstract][Full Text] [Related]
14. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
[TBL] [Abstract][Full Text] [Related]
15. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.
Jansåker F; Frimodt-Møller N; Sjögren I; Dahl Knudsen J
J Antimicrob Chemother; 2014 Mar; 69(3):769-72. PubMed ID: 24107388
[TBL] [Abstract][Full Text] [Related]
16. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility to mecillinam of Escherichia coli strains isolated from the urine of pregnant women.
Duployez C; Loiez C; Cattoen C; Descamps D; Wallet F; Vachée A;
Med Mal Infect; 2016 Dec; 46(8):436-441. PubMed ID: 27609597
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Titelman E; Iversen A; Kalin M; Giske CG
Microb Drug Resist; 2012 Apr; 18(2):189-92. PubMed ID: 22204597
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens.
Mendes RE; Rhomberg PR; Lister T; Cotroneo N; Rubio A; Flamm RK
Microb Drug Resist; 2020 Apr; 26(4):319-328. PubMed ID: 31596663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
